Smith & Nephew SNATS, Inc. (NYSE:SNN) Receives Consensus Recommendation of "Hold" from Analysts

Smith & Nephew SNATS, Inc. (NYSE:SNN - Get Free Report) has been given an average rating of "Hold" by the six brokerages that are currently covering the firm, Marketbeat reports. Six research analysts have rated the stock with a hold recommendation. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $28.00.

SNN has been the topic of a number of recent analyst reports. Canaccord Genuity Group upped their price target on shares of Smith & Nephew SNATS from $27.00 to $28.00 and gave the stock a "hold" rating in a research note on Thursday, May 1st. Wall Street Zen upgraded shares of Smith & Nephew SNATS from a "buy" rating to a "strong-buy" rating in a research report on Wednesday, February 26th. Hsbc Global Res cut shares of Smith & Nephew SNATS from a "strong-buy" rating to a "hold" rating in a report on Friday, April 25th. HSBC lowered Smith & Nephew SNATS from a "buy" rating to a "hold" rating in a research note on Friday, April 25th. Finally, UBS Group downgraded Smith & Nephew SNATS from a "buy" rating to a "neutral" rating in a research note on Wednesday, March 12th.

Hedge Funds Weigh In On Smith & Nephew SNATS

Hedge funds have recently added to or reduced their stakes in the business. PNC Financial Services Group Inc. grew its position in shares of Smith & Nephew SNATS by 4.6% in the fourth quarter. PNC Financial Services Group Inc. now owns 9,120 shares of the medical equipment provider's stock valued at $224,000 after purchasing an additional 399 shares during the last quarter. Hexagon Capital Partners LLC grew its holdings in Smith & Nephew SNATS by 63.3% during the 1st quarter. Hexagon Capital Partners LLC now owns 1,047 shares of the medical equipment provider's stock valued at $30,000 after buying an additional 406 shares during the last quarter. National Bank of Canada FI increased its position in Smith & Nephew SNATS by 36.5% during the fourth quarter. National Bank of Canada FI now owns 1,667 shares of the medical equipment provider's stock worth $41,000 after buying an additional 446 shares in the last quarter. Geneos Wealth Management Inc. raised its holdings in shares of Smith & Nephew SNATS by 15.0% in the first quarter. Geneos Wealth Management Inc. now owns 4,149 shares of the medical equipment provider's stock worth $118,000 after acquiring an additional 541 shares during the last quarter. Finally, Signaturefd LLC raised its holdings in shares of Smith & Nephew SNATS by 4.3% in the fourth quarter. Signaturefd LLC now owns 15,772 shares of the medical equipment provider's stock worth $388,000 after acquiring an additional 653 shares during the last quarter. 25.64% of the stock is currently owned by hedge funds and other institutional investors.

Smith & Nephew SNATS Price Performance

Shares of Smith & Nephew SNATS stock traded down $0.71 during trading on Friday, reaching $28.60. The company's stock had a trading volume of 1,310,615 shares, compared to its average volume of 803,217. The business has a 50 day moving average price of $28.09 and a 200-day moving average price of $26.89. Smith & Nephew SNATS has a 12-month low of $23.69 and a 12-month high of $31.72. The company has a market capitalization of $12.52 billion, a P/E ratio of 13.24, a price-to-earnings-growth ratio of 0.90 and a beta of 0.68. The company has a quick ratio of 1.33, a current ratio of 2.89 and a debt-to-equity ratio of 0.62.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.